


A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer.

Study Design:



Planned No. of patients: 78

Current accrual: 63

Stratification:

- Number of prior lines (primary adv disease vs. 1st relapse vs. ≥2 relapses)
- Measurable vs. evaluable disease
- Prior use of MPA/Megace

Other important information: *Slow recruitment in the PALEO study. MITO still pending regarding approvals from CA and EC*